Author:
Asmar Ramsey,Rizvi Naiyer A.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference44 articles.
1. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.;Topalian;N Engl J Med,2012
2. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer.;Gettinger;J Clin Oncol,2015
3. Hallmarks of cancer: the next generation.;Hanahan;Cell,2011
4. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother (1991).;Jansen,1992
5. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.;Butts;Lancet Oncol,2014
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献